Amr Makady

1.9k total citations · 2 hit papers
27 papers, 1.2k citations indexed

About

Amr Makady is a scholar working on Economics and Econometrics, General Health Professions and Statistics and Probability. According to data from OpenAlex, Amr Makady has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Economics and Econometrics, 11 papers in General Health Professions and 4 papers in Statistics and Probability. Recurrent topics in Amr Makady's work include Health Systems, Economic Evaluations, Quality of Life (24 papers), Pharmaceutical Economics and Policy (13 papers) and Healthcare cost, quality, practices (6 papers). Amr Makady is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (24 papers), Pharmaceutical Economics and Policy (13 papers) and Healthcare cost, quality, practices (6 papers). Amr Makady collaborates with scholars based in Netherlands, United Kingdom and United States. Amr Makady's co-authors include Wim Goettsch, Olaf H. Klungel, Hans L. Hillege, Anthonius de Boer, Rosanna Tarricone, Harold C. Sox, David Madigan, John B. Watkins, C. Daniel Mullins and Hans‐Georg Eichler and has published in prestigious journals such as PLoS ONE, Social Science & Medicine and Health and Quality of Life Outcomes.

In The Last Decade

Amr Makady

26 papers receiving 1.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making

2017 327 citations Marc L. Berger, Harold C. Sox et al. Value in Health profile →
What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews

2017 226 citations Amr Makady, Anthonius de Boer et al. Value in Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amr Makady Netherlands	12	643	232	171	122	92	27	1.2k
Diana Brixner United States	10	461 0.7×	143 0.6×	194 1.1×	75 0.6×	96 1.0×	37	977
Nicholas S. Downing United States	19	757 1.2×	178 0.8×	176 1.0×	205 1.7×	78 0.8×	46	1.9k
Spencer Phillips Hey United States	21	479 0.7×	282 1.2×	213 1.2×	268 2.2×	228 2.5×	68	1.5k
Gerry Gray United States	6	341 0.5×	239 1.0×	95 0.6×	155 1.3×	169 1.8×	9	1.4k
Jenerius A. Aminawung United States	16	526 0.8×	135 0.6×	280 1.6×	175 1.4×	161 1.8×	42	1.4k
Gregory W. Daniel United States	20	343 0.5×	138 0.6×	90 0.5×	132 1.1×	137 1.5×	46	1.5k
Rachel E. Sherman United States	13	524 0.8×	325 1.4×	128 0.7×	250 2.0×	206 2.2×	18	2.1k
Bennett Levitan United States	20	530 0.8×	96 0.4×	265 1.5×	94 0.8×	41 0.4×	80	1.3k
Melissa A. Robb United States	10	555 0.9×	348 1.5×	155 0.9×	272 2.2×	215 2.3×	12	2.2k
Louis Dron Canada	15	192 0.3×	227 1.0×	79 0.5×	130 1.1×	103 1.1×	35	1.2k

Countries citing papers authored by Amr Makady

Since Specialization

Citations

This map shows the geographic impact of Amr Makady's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amr Makady with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amr Makady more than expected).

Fields of papers citing papers by Amr Makady

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amr Makady. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amr Makady. The network helps show where Amr Makady may publish in the future.

Co-authorship network of co-authors of Amr Makady

This figure shows the co-authorship network connecting the top 25 collaborators of Amr Makady. A scholar is included among the top collaborators of Amr Makady based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amr Makady. Amr Makady is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lysen, Thom S., et al.. (2024). Real world insights for psoriasis: the association of severity of skin lesions with work productivity, medical consumption costs and quality of life. Journal of Dermatological Treatment. 35(1). 2332615–2332615. 3 indexed citations

Exel, Job van, et al.. (2023). Public preferences for the allocation of societal resources over different healthcare purposes. Social Science & Medicine. 341. 116536–116536. 2 indexed citations

Annemans, Lieven & Amr Makady. (2020). TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases. Orphanet Journal of Rare Diseases. 15(1). 127–127. 22 indexed citations

Makady, Amr, et al.. (2019). The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders. PLoS ONE. 14(11). e0225626–e0225626. 6 indexed citations

Makady, Amr, et al.. (2019). Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia. PLoS ONE. 14(2). e0212328–e0212328. 18 indexed citations

Dekker, Marieke J. H. J., Jacoline C. Bouvy, Robin Thompson, et al.. (2019). Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease. Frontiers in Medicine. 6. 73–73. 13 indexed citations

Makady, Amr, et al.. (2019). Conditional Financing of Drugs in the Netherlands: Past, Present, and Future—Results From Stakeholder Interviews. Value in Health. 22(4). 399–407. 13 indexed citations

Bouvy, Jacoline C., Páll Jónsson, Antonella Santuccione Chadha, et al.. (2018). Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease. CNS Drugs. 32(12). 1085–1090. 4 indexed citations

Makady, Amr, et al.. (2018). Use of Social Media in the Assessment of Relative Effectiveness: Explorative Review With Examples From Oncology. JMIR Cancer. 4(1). e11–e11. 12 indexed citations

10.

Makady, Amr, Bettina Ryll, Gilliosa Spurrier, et al.. (2018). Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study. Health and Quality of Life Outcomes. 16(1). 222–222. 9 indexed citations

11.

Makady, Amr, et al.. (2018). Implementing managed entry agreements in practice: The Dutch reality check. Health Policy. 123(3). 267–274. 37 indexed citations

12.

Berger, Marc L., Harold C. Sox, Richard J. Willke, et al.. (2017). Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making. Value in Health. 20(8). 1003–1008. 327 indexed citations breakdown →

13.

Makady, Amr, Páll Jónsson, Anne d’Andon, et al.. (2017). Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. PharmacoEconomics. 36(3). 359–368. 75 indexed citations

14.

Makady, Amr, et al.. (2017). Implementing Managed Entry Agreements in Practice: The Dutch Reality Check. Value in Health. 20(9). A702–A702. 10 indexed citations

15.

Makady, Amr, Bettina Ryll, Keith R. Abrams, et al.. (2017). Practicalities Of Using Real-World Evidence (RWE) In Comparative Effectiveness Research (CER): Learnings From Imi-Getreal. Value in Health. 20(9). A692–A692.

16.

Makady, Amr, Anthonius de Boer, Hans L. Hillege, Olaf H. Klungel, & Wim Goettsch. (2017). What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews. Value in Health. 20(7). 858–865. 226 indexed citations breakdown →

17.

Makady, Amr, et al.. (2016). What is Real-World Data?: A Review of Definitions Based on Literature & Stakeholder Interviews. Value in Health. 19(7). A502–A502. 2 indexed citations

18.

Makady, Amr, et al.. (2016). Policies for Use of Real-World Data in Health Technology Assessment: A Comparative Study of 6 HTA Agencies. Value in Health. 19(7). A501–A502. 1 indexed citations

19.

Makady, Amr, et al.. (2016). Implementation of Conditional Reimbursement Schemes in HTA Practice: Experiences from the Netherlands. Value in Health. 19(7). A348–A348. 1 indexed citations

20.

Makady, Amr & Wim Goettsch. (2015). Review of Policies And Perspectives on Real-World Data for Drug Development and Assessment (Imi-Getreal Deliverable). Value in Health. 18(7). A567–A567. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact